EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Post‐Relapse Outcomes of Older Patients With NPM1 ‐Mutated AML Are Favorable With Allo Transplant in Second Remission

Avraham Frisch, Chezi Ganzel iD, Yishai Ofran, Baher Krayem, Arnon Haran, Vladimir Vainstein, Shlomzion Aumann, Noa Gross Even-Zohar, Boaz Nachmias iD

European Journal of Haematology · 2025

DOI: 10.1111/ejh.14375 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Haematology, 2025. Verfasst von Avraham Frisch und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology and Bone Marrow Transplantation, Rambam Health Care Campus, and Rappaport Faculty of Medicine-Technion, Haifa, Israel. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute, Mutation, Nuclear Proteins, Hematopoietic Stem Cell Transplantation. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Molecular assessment of measurable residual disease (MRD) in NPM1 ‐mutated AML patients is a powerful prognostic tool to identify the risk of relapse. There is limited data regarding MRD‐guided decisions against alloSCT in elderly patients and FLT3 –ITD co‐mutation. We describe the outcome of NPM1 ‐mutated AML patients in whom alloSCT was deferred based on ELN 2017 risk and MRD response. We report a relapse rate of 53% in this group, with a much higher incidence for older than 60 years patients than for younger patients (73% vs. 37%). When comparing outcomes of alloSCT in CR1 to intensive chemotherapy consolidation within each age group, patients over 60 years and patients with FLT3–ITD co‐mutation had significantly lower RFS with intensive consolidation. Yet, in all subgroups, the lower RFS did not translate into OS difference, suggesting that relapsed NPM1 patients can often be salvaged and consequently achieve long‐term remission. Our study supports the use of MRD response along with FLT3 –ITD status in the decision to use post‐remission therapy. We demonstrate that older patients and patients with FLT3 –ITD‐mutated AML have a high relapse rate but can be salvaged, leading to long‐term survival.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukemia, Myeloid, AcuteMutationNuclear ProteinsHematopoietic Stem Cell TransplantationHumansNucleophosminAgedMaleMiddle AgedFemalefms-Like Tyrosine Kinase 3AdultRemission InductionPrognosisTreatment OutcomeRecurrenceNeoplasm, ResidualTransplantation, HomologousAge FactorsAged, 80 and overYoung Adult

Stichwörter der Autor:innen

Acute myeloid leukemiaMeasurable residual diseaseNPM1relapse

Substanzen

NucleophosminNPM1 protein, humanNuclear Proteinsfms-Like Tyrosine Kinase 3FLT3 protein, human

Autor:innen und Institutionen

  • Department of Hematology and Bone Marrow Transplantation, Rambam Health Care Campus, and Rappaport Faculty of Medicine-Technion, Haifa, Israel.
  • The Hematology and Stem Cell Transplantation Department and the Eisenberg R&D Authority, Shaare Zedek Medical Center; Faculty of Medicine, Hebrew University of Jerusalem, Israel.
  • Department of Hematology, Hadassah Medical Center and Faculty of Medicine, Hebrew University of Jerusalem, Israel.

ORCID-Profile: Chezi Ganzel, Boaz Nachmias

Zitieren

APA

Frisch, A., Ganzel, C., Ofran, Y., Krayem, B., Haran, A., Vainstein, V., Aumann, S., Even-Zohar, N. G., & Nachmias, B. (2025). Post‐Relapse Outcomes of Older Patients With NPM1 ‐Mutated AML Are Favorable With Allo Transplant in Second Remission. European Journal of Haematology. https://doi.org/10.1111/ejh.14375

Vancouver

Frisch A, Ganzel C, Ofran Y, Krayem B, Haran A, Vainstein V, et al. Post‐Relapse Outcomes of Older Patients With NPM1 ‐Mutated AML Are Favorable With Allo Transplant in Second Remission. European Journal of Haematology. 2025. doi:10.1111/ejh.14375

BibTeX
@article{Frisch2025,
  author = {Frisch, Avraham and Ganzel, Chezi and Ofran, Yishai and Krayem, Baher and Haran, Arnon and Vainstein, Vladimir and Aumann, Shlomzion and Even-Zohar, Noa Gross and Nachmias, Boaz},
  title = {Post‐Relapse Outcomes of Older Patients With NPM1 ‐Mutated AML Are Favorable With Allo Transplant in Second Remission},
  journal = {European Journal of Haematology},
  year = {2025},
  doi = {10.1111/ejh.14375}
}
Kostenlos starten →